Literature DB >> 27869170

Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals.

Y Wang1,2, Z Ou1,2, Y Sun2, S Yeh2, X Wang1, J Long1, C Chang2,3.   

Abstract

Early studies demonstrated that male melanoma patients have worse survival than female patients, yet the detailed mechanisms for this gender difference remain unclear. We analyzed around 100 cases of human melanoma and found that androgen receptor (AR) positive melanoma patients have worse survival outcomes compared with AR-negative melanoma patients. Here we report that AR can have positive roles to increase melanoma cell invasion in multiple cell lines in vitro and a mouse model in vivo. Mechanism dissection suggest that AR increases melanoma cell invasion via modulating the MITF-AXL signals via altering the miRNA-539-3p/USP13 signaling to increase MITF protein degradation through a reduction of de-ubiquitination. Restoring MITF can reverse AR-enhanced melanoma cell invasion. Together, our results demonstrate that AR can promote melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signal and targeting this newly identified signal with AR degradation enhancer ASC-J9 may help us to better suppress the melanoma metastasis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27869170     DOI: 10.1038/onc.2016.330

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  48 in total

1.  Gender-related differences in outcome for melanoma patients.

Authors:  Charles R Scoggins; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; James S Goydos; Peter D Beitsch; Marshall M Urist; Stephan Ariyan; Jeffrey J Sussman; Michael J Edwards; Anees B Chagpar; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters
Journal:  Ann Surg       Date:  2006-05       Impact factor: 12.969

2.  Regulation of MITF stability by the USP13 deubiquitinase.

Authors:  Xiansi Zhao; Brian Fiske; Akinori Kawakami; Juying Li; David E Fisher
Journal:  Nat Commun       Date:  2011-08-02       Impact factor: 14.919

3.  ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF signaling pathway.

Authors:  Dalin He; Lei Li; Guodong Zhu; Liang Liang; Zhenfeng Guan; Luke Chang; Yuan Chen; Shuyuan Yeh; Chawnshang Chang
Journal:  Cancer Res       Date:  2014-06-12       Impact factor: 12.701

4.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.

Authors:  Suzanne Carreira; Jane Goodall; Laurence Denat; Mercedes Rodriguez; Paolo Nuciforo; Keith S Hoek; Alessandro Testori; Lionel Larue; Colin R Goding
Journal:  Genes Dev       Date:  2006-12-15       Impact factor: 11.361

5.  Genomic analysis of metastasis reveals an essential role for RhoC.

Authors:  E A Clark; T R Golub; E S Lander; R O Hynes
Journal:  Nature       Date:  2000-08-03       Impact factor: 49.962

Review 6.  Early detection and treatment of skin cancer.

Authors:  A F Jerant; J T Johnson; C D Sheridan; T J Caffrey
Journal:  Am Fam Physician       Date:  2000-07-15       Impact factor: 3.292

Review 7.  Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver.

Authors:  C Chang; S O Lee; S Yeh; T M Chang
Journal:  Oncogene       Date:  2013-07-22       Impact factor: 9.867

8.  Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma.

Authors:  Wen-Lung Ma; Cheng-Lung Ma; Cheng-Lung Hsu; Ming-Heng Wu; Chun-Te Wu; Cheng-Chia Wu; Jiann-Jyh Lai; Yuh-Shan Jou; Chun-Wei Chen; Shuyuan Yeh; Chawnshang Chang
Journal:  Gastroenterology       Date:  2008-05-22       Impact factor: 22.682

9.  Therapy-induced tumour secretomes promote resistance and tumour progression.

Authors:  Anna C Obenauf; Yilong Zou; Andrew L Ji; Sakari Vanharanta; Weiping Shu; Hubing Shi; Xiangju Kong; Marcus C Bosenberg; Thomas Wiesner; Neal Rosen; Roger S Lo; Joan Massagué
Journal:  Nature       Date:  2015-03-25       Impact factor: 49.962

10.  Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.

Authors:  Kouji Izumi; Lei-Ya Fang; Atsushi Mizokami; Mikio Namiki; Lei Li; Wen-Jye Lin; Chawnshang Chang
Journal:  EMBO Mol Med       Date:  2013-08-27       Impact factor: 12.137

View more
  16 in total

Review 1.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

2.  miR-337 can be a key negative regulator in melanoma.

Authors:  Wanan Xiao; Enyang Yao; Wei Zheng; Feng Tian; Lijie Tian
Journal:  Cancer Biol Ther       Date:  2017-05-12       Impact factor: 4.742

3.  Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.

Authors:  Christopher P Vellano; Michael G White; Miles C Andrews; Manoj Chelvanambi; Russell G Witt; Joseph R Daniele; Mark Titus; Jennifer L McQuade; Fabio Conforti; Elizabeth M Burton; Matthew J Lastrapes; Gabriel Ologun; Alexandria P Cogdill; Golnaz Morad; Peter Prieto; Alexander J Lazar; Yanshuo Chu; Guangchun Han; M A Wadud Khan; Beth Helmink; Michael A Davies; Rodabe N Amaria; Jeffrey J Kovacs; Scott E Woodman; Sapna Patel; Patrick Hwu; Michael Peoples; Jeffrey E Lee; Zachary A Cooper; Haifeng Zhu; Guang Gao; Hiya Banerjee; Mike Lau; Jeffrey E Gershenwald; Anthony Lucci; Emily Z Keung; Merrick I Ross; Laura Pala; Eleonora Pagan; Rossana Lazcano Segura; Qian Liu; Mikayla S Borthwick; Eric Lau; Melinda S Yates; Shannon N Westin; Khalida Wani; Michael T Tetzlaff; Lauren E Haydu; Mikhila Mahendra; XiaoYan Ma; Christopher Logothetis; Zachary Kulstad; Sarah Johnson; Courtney W Hudgens; Ningping Feng; Lorenzo Federico; Georgina V Long; P Andrew Futreal; Swathi Arur; Hussein A Tawbi; Amy E Moran; Linghua Wang; Timothy P Heffernan; Joseph R Marszalek; Jennifer A Wargo
Journal:  Nature       Date:  2022-06-15       Impact factor: 69.504

4.  Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.

Authors:  Ning Liu; Yi Chen; Lei Yang; Qiancheng Shi; Yanwen Lu; Wenliang Ma; Xiaodong Han; Hongqian Guo; Dongmei Li; Weidong Gan
Journal:  Clin Transl Med       Date:  2022-04

5.  Host Characteristics and Risk of Incident Melanoma by Breslow Thickness.

Authors:  Wen-Qing Li; Eunyoung Cho; Shaowei Wu; Suyun Li; Natalie H Matthews; Abrar A Qureshi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-19       Impact factor: 4.254

6.  The lncRNA SLNCR Recruits the Androgen Receptor to EGR1-Bound Genes in Melanoma and Inhibits Expression of Tumor Suppressor p21.

Authors:  Karyn Schmidt; Johanna S Carroll; Elaine Yee; Dolly D Thomas; Leon Wert-Lamas; Steven C Neier; Gloria Sheynkman; Justin Ritz; Carl D Novina
Journal:  Cell Rep       Date:  2019-05-21       Impact factor: 9.423

7.  Structure-Activity Relationship (SAR) Study of Spautin-1 to Entail the Discovery of Novel NEK4 Inhibitors.

Authors:  Mathias Elsocht; Philippe Giron; Laila Maes; Wim Versées; Gustavo J Gutierrez; Jacques De Grève; Steven Ballet
Journal:  Int J Mol Sci       Date:  2021-01-10       Impact factor: 5.923

8.  miR‑27a promotes human breast cancer cell migration by inducing EMT in a FBXW7‑dependent manner.

Authors:  Guobin Jiang; Weiwu Shi; Hongyan Fang; Xiaohua Zhang
Journal:  Mol Med Rep       Date:  2018-10-24       Impact factor: 2.952

9.  NEDD4 Negatively Regulates GITR via Ubiquitination in Immune Microenvironment of Melanoma.

Authors:  Yu Guo; Lichang Yang; Shaorong Lei; Wuyuan Tan; Jianhong Long
Journal:  Onco Targets Ther       Date:  2019-12-04       Impact factor: 4.147

10.  Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis.

Authors:  Min Ma; Soumitra Ghosh; Daniele Tavernari; Atul Katarkar; Andrea Clocchiatti; Luigi Mazzeo; Anastasia Samarkina; Justine Epiney; Yi-Ru Yu; Ping-Chih Ho; Mitchell P Levesque; Berna C Özdemir; Giovanni Ciriello; Reinhard Dummer; G Paolo Dotto
Journal:  J Exp Med       Date:  2021-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.